Promoted Content Promoted Content

X

Find Neurology Drugs in Phase II Clinical Development in SWITZERLAND

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NRD135S.E1

            Therapeutic Area: Neurology Product Name: NRD.E1

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: GEM Global Yield

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement January 28, 2021

            Details:

            The proceeds from this financing will be used to progress the clinical development of Novaremed’s lead product, NRD135S.E1, an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy (PDPN).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ADX71149

            Therapeutic Area: Neurology Product Name: ADX71149

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2021

            Details:

            The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dipraglurant

            Therapeutic Area: Neurology Product Name: ADX48621

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co

            Deal Size: $11.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering January 11, 2021

            Details:

            Addex intends to use the net proceeds from the global offering, mainly to advance development of its portfolio of proprietary drug candidates based on its allosteric modulator development capabilities. These include dipraglurant for use in Parkinson's disease and dystonia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NRD135S.E1

            Therapeutic Area: Neurology Product Name: NRD135S.E1

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 18, 2020

            Details:

            In a Phase 2a Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2b study in PDPN patients in USA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NOE-101

            Therapeutic Area: Neurology Product Name: NOE-101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sofinnova Partners

            Deal Size: $59.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 01, 2020

            Details:

            Financing will advance the development of four clinical-stage product candidates including lead product NOE-101. The product candidates will be developed in neurological indications with severe unmet need.